| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
43,980,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
66,200 |
Avg
Vol: |
66,015 |
| 52
Week Range: |
$0.173 - $0.173 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ESSA Pharma is a clinical stage pharmaceutical company. Co. is focused on developing therapies for the treatment of prostate cancer in patients whose disease is progressing despite treatment with care therapies, including anti-androgen drugs such as abiraterone, enzalutamide, apalutamide, and darolutamide. Co.'s series of investigational compounds, including its product candidate EPI-7386, is used in patients with castration-resistant prostate cancer through anti-hormone-based therapies. The compounds are designed to disrupt the androgen receptor (AR) signaling pathway and prevent AR activation through selective binding to the N-terminal domain of the AR.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
108,953 |
108,953 |
1,035,445 |
| Total Buy Value |
$0 |
$574,148 |
$574,148 |
$3,342,196 |
| Total People Bought |
0 |
2 |
2 |
4 |
| Total Buy Transactions |
0 |
4 |
4 |
11 |
| Total Shares Sold |
75,364 |
77,781 |
77,781 |
350,621 |
| Total Sell Value |
$772,109 |
$793,577 |
$793,577 |
$1,522,629 |
| Total People Sold |
1 |
1 |
1 |
2 |
| Total Sell Transactions |
4 |
6 |
6 |
11 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Glickman Richard M |
|
• • – |
2024-04-24 |
4 |
OE |
$4.90 |
$18,375 |
D/D |
3,750 |
43,240 |
|
- |
|
| Virsik Peter |
Chief Operating Officer |
• • – |
2024-04-05 |
4 |
AS |
$7.94 |
$5,510 |
D/D |
(694) |
11,940 |
|
- |
|
| Virsik Peter |
Chief Operating Officer |
• – – |
2024-03-05 |
4 |
AS |
$8.98 |
$6,232 |
D/D |
(694) |
12,634 |
|
- |
|
| Virsik Peter |
Chief Operating Officer |
• – – |
2024-02-06 |
4 |
AS |
$10.29 |
$748,927 |
D/D |
(72,782) |
13,328 |
|
- |
|
| Virsik Peter |
Chief Operating Officer |
• – – |
2024-02-06 |
4 |
OE |
$3.23 |
$235,086 |
D/D |
72,782 |
86,110 |
|
- |
|
| Virsik Peter |
Chief Operating Officer |
• – – |
2024-02-05 |
4 |
AS |
$9.25 |
$11,440 |
D/D |
(1,194) |
13,328 |
|
- |
|
| Virsik Peter |
Chief Operating Officer |
• – – |
2024-02-05 |
4 |
OE |
$3.23 |
$1,615 |
D/D |
500 |
13,828 |
|
- |
|
| Virsik Peter |
Chief Operating Officer |
• – – |
2024-01-16 |
4 |
AS |
$10.01 |
$17,197 |
D/D |
(1,718) |
14,022 |
|
- |
|
| Virsik Peter |
Chief Operating Officer |
• – – |
2024-01-16 |
4 |
OE |
$3.23 |
$5,549 |
D/D |
1,718 |
15,740 |
|
- |
|
| Virsik Peter |
Chief Operating Officer |
• – – |
2024-01-05 |
4 |
AS |
$6.11 |
$4,271 |
D/D |
(699) |
14,022 |
|
- |
|
| Parkinson David Ross |
Chief Executive Officer |
• • – |
2023-12-14 |
4 |
B |
$2.30 |
$21,213 |
D/D |
9,223 |
65,675 |
0.01 |
- |
|
| Berger Franklin M |
|
– • – |
2023-11-21 |
4 |
B |
$5.73 |
$133,274 |
D/D |
23,259 |
784,404 |
0.01 |
- |
|
| Requadt Scott |
Director |
– • – |
2023-11-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(12,500) |
30,002 |
|
- |
|
| Berger Franklin M |
|
– • – |
2023-11-03 |
4 |
B |
$5.99 |
$98,661 |
D/D |
16,471 |
760,875 |
0.01 |
- |
|
| Berger Franklin M |
|
– • – |
2023-11-02 |
4 |
B |
$5.35 |
$321,000 |
D/D |
60,000 |
744,404 |
0.01 |
- |
|
| Requadt Scott |
Director |
– • – |
2023-10-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(17,502) |
42,502 |
|
- |
|
| Wood David S. |
Chief Financial Officer |
• – – |
2022-12-30 |
4 |
B |
$2.60 |
$21,585 |
D/D |
8,302 |
33,343 |
2.74 |
- |
|
| Parkinson David Ross |
Chief Executive Officer |
• • – |
2022-12-30 |
4 |
B |
$2.60 |
$7,974 |
D/D |
3,067 |
56,542 |
2.81 |
- |
|
| Parkinson David Ross |
Chief Executive Officer |
• • – |
2022-12-22 |
4 |
B |
$2.39 |
$51,067 |
D/D |
21,367 |
53,475 |
2.81 |
- |
|
| Berger Franklin M |
Director |
– • – |
2022-12-21 |
4 |
S |
$2.41 |
$174,401 |
D/D |
(72,223) |
684,404 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2022-12-20 |
4 |
S |
$2.53 |
$110,351 |
D/D |
(43,617) |
756,627 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2022-12-16 |
4 |
S |
$2.67 |
$133,500 |
D/D |
(50,000) |
800,244 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2022-12-15 |
4 |
S |
$2.86 |
$235,800 |
D/D |
(82,000) |
850,244 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2022-12-14 |
4 |
S |
$3.00 |
$75,000 |
D/D |
(25,000) |
932,244 |
|
- |
|
| Bb Biotech Ag |
10% Owner |
– – • |
2022-07-18 |
4 |
B |
$3.16 |
$946,740 |
D/D |
300,000 |
5,879,583 |
2.45 |
- |
|
43 Records found
|
|
Page 1 of 2 |
|
|
